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Activation of complement is a key determinant of neuropathology
and disability after traumatic brain injury (TBI), and inhibition is
neuroprotective. However, systemic complement is essential to
fight infections, a critical complication of TBI. We describe a
targeted complement inhibitor, comprising complement receptor
of the Ig superfamily (CRIg) fused with complement regulator CD59a,
designed to inhibit membrane attack complex (MAC) assembly at
sites of C3b/iC3b deposition. CRIg and CD59a were linked via the
IgG2a hinge, yielding CD59-2a-CRIg dimer with increased iC3b/C3b
binding avidity and MAC inhibitory activity. CD59-2a-CRIg inhibited
MAC formation and prevented complement-mediated lysis in vitro.
CD59-2a-CRIg dimer bound C3b-coated surfaces with submicromolar
affinity (KD). In experimental TBI, CD59-2a-CRIg administered post-
trauma homed to sites of injury and significantly reduced MAC
deposition, microglial accumulation, mitochondrial stress, and axonal
damage and enhanced neurologic recovery compared with placebo
controls. CD59-2a-CRIg inhibited MAC-induced inflammasome activa-
tion and IL-1β production in microglia. Given the important anti-
infection roles of complement opsonization, site-targeted inhibition
of MAC should be considered to promote recovery postneurotrauma.
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Cognitive, behavioral, and emotional sequelae of traumaticbrain injury (TBI) are largely due to neuroaxonal damage
secondary to the mechanical injury (1, 2). Complement is an
early determinant of posttraumatic neuroinflammation and sec-
ondary neuropathology (3–7); therefore, timely intervention to
block complement activation may reduce neuroinflammation,
neurodegeneration, and neurologic decline. Previous studies showed
that complement inhibition protects in experimental TBI; however,
most agents targeted the C3 convertase, the point of activation
pathway convergence, resulting in broad inhibition of complement
(8, 9). Others interfered with C5a, a potent inflammatory mediator
(10), or with activation of the alternative pathway (11), a major
player in the disease pathophysiology (12). Complement activa-
tion products are also key to effective immune defense against
infections (13), a critical complication in TBI patients; therefore,
the stage and location of complement inhibition is critically im-
portant for effective therapy in TBI, blocking detrimental effects
while maintaining protective functions.
We recently demonstrated that inhibition of the most down-
stream complement activation product, the membrane attack
complex (MAC), effectively prevents secondary neurologic damage
and deficit in experimental TBI (14). MAC inhibition was achieved
using an antisense oligonucleotide targeting C6, an essential MAC
component, administered for 1 wk before injury (14). A clinically
relevant anticomplement therapy in TBI must rapidly block com-
plement activation when administered postinjury and be targeted to
the activation site to minimize infection risk. We previously
reported a murine CD59a-based targeted therapeutic using com-
plement receptor of the Ig superfamily (CRIg), which binds C3
fragments, as the homing domain (15). In this article, we describe
the development of this fusion protein, demonstrate its capacity
to rapidly and specifically inhibit MAC at sites of complement
activation, and test its therapeutic potential in experimental TBI.
The construct, termed CD59-2a-CRIg, comprises CD59a linked
to CRIg via the murine IgG2a hinge. CD59a prevents assembly
of MAC in cell membranes (16), whereas CRIg binds C3b/iC3b
deposited at sites of complement activation (17). The IgG2a
hinge promotes dimerization to increase ligand avidity. CD59-
2a-CRIg protected in the TBI model, demonstrating that site-
targeted anti-MAC therapeutics may be effective in prevention
of secondary neuropathology and improve neurologic recovery
when administered post-TBI in patients.
Results
Generation and in Vitro Characterization of CD59-2a-CRIg. CD59-2a-
CRIg was generated by expressing the extracellular domains of
CD59a and CRIg linked through the murine IgG2a hinge to pro-
mote dimerization, thus increasing avidity for ligands (Fig. 1A).
CD59-2a-CRIg, isolated from the culture supernatant of transfected
CHO cells and analyzed by SDS/PAGE, migrated as two bands with
an apparent molecular mass of 83 kDa and 45 kDa (Fig. 1B). These
were separated by size exclusion chromatography (Superdex 200),
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yielding two peaks consistent with the expected masses of mono-
mer and dimer (Fig. 1C). Both were recognized by anti-CRIg
monoclonal antibody (mAb), and reducing SDS/PAGE demon-
strated that the dimer was disulphide bonded (Fig. 1D and E). The
relative ratio of monomer:dimer, measured from the peak area,
was 55%:45%.
The capacities of CD59-2a-CRIg to inhibit MAC formation
and protect cells from complement lysis were assessed by hae-
molysis assay; guinea pig erythrocyte (GPE) and rat serum were
used as the target and complement source, respectively. GPE
was incubated with serial dilutions of CD59-2a-CRIg (55%:45%,
dimer:monomer) and rat serum, dose titred to cause 90% lysis.
CD59-2a-CRIg inhibited complement activation in a dose-
dependent manner (Fig. 1F). Previous studies have reported that
CRIg blocks alternative pathway activation in vitro (18). To con-
firm that haemolysis inhibition by CD59-2a-CRIg was due to
CD59a inhibition of MAC formation, the CD59a moiety was
blocked using anti-CD59a mAb; CD59a-blocked cells were no
longer protected from lysis (Fig. 1F). To further test the function
of each domain, CD59-2a-CRIg was incubated with GPE pre-
coated with C3b and C5b67, and the free agent was washed away
and the MAC developed with C3-deficient mouse serum. Lysis
was blocked, demonstrating that CRIg localized the agent to the
opsonized surface, and the CD59a domain blocked MAC forma-
tion (Fig. S1A).
We performed surface plasmon resonance (SPR) analysis to
measure affinity of the CD59-2a-CRIg monomer (Fig. 2A) and
dimer (Fig. 2B) for mouse C3b. A mouse C3b-opsonized chip
surface was generated via the alternative pathway by flowing
factor B and factor D over a surface coated with a nidus (50RU)
of human C3b. C3bBb thus formed catalyzed cleavage of mouse
C3 flowed across, resulting in abundant covalent deposition of
mouse C3b (700RU). The equilibrium dissociation constant (KD) for
the monomer and dimer was determined by steady-state analysis.
The apparent affinity (KD) was 4.65 μM for monomer and eightfold
higher (0.55 μM) for the dimer, demonstrating the impact of di-
merization on affinity of CD59-2a-CRIg for the C3b ligand and
confirming that both CRIg domains bind simultaneously to separate
C3b molecules to deliver avidity.
In Vivo Localization of CD59-2a-CRIg. To test CD59-2a-CRIg
homing to the site of injury, anti-CRIg mAb was used to localize
the agent in brains of treated mice at 72 h post-TBI (Fig. 3).
Mice subjected to TBI were treated with 10 or 20 mg/kg CD59-
2a-CRIg (mixture of dimer and monomer), or PBS, immediately
postinjury (i.v.), according to the described protocol (Materials
and Methods). Analysis of consecutive brain sections showed
localization of CD59-2a-CRIg to the impact site in mice treated
with 20 mg/kg CD59-2a-CRIg (Fig. 3A); localization was not de-
tected at 10 mg/kg, indicating that the higher dose was required to
adequately target the injury site. The C3 activation fragment (C3b/
iC3b/C3dg) deposition colocalized with CD59-2a-CRIg (Fig. 3B),
but immunostaining for MAC (14, 19–22) was negative in corre-
sponding areas (Fig. 3C); in contrast, brain tissue from PBS-
treated TBI controls showed C3 fragments (Fig. 3E) and MAC
(Fig. 3F) deposited at the site of injury, demonstrating blockade of
MAC formation by CD59-2a-CRIg in situ. Anti-CRIg mAb did
not detect endogenous CRIg in mouse brain (Fig. 3D), likely be-
cause of low expression in brain parenchyma (23). Together, these
data demonstrate that CD59-2a-CRIg localizes to areas of com-
plement activation and inhibits MAC deposition in vivo.
Fig. 1. Generation and functional analysis of CD59-
2a-CRIg. (A) The extracellular domain of mouse
CD59a was fused through the mouse IgG2a hinge to
the N terminus of mouse CRIg to generate CD59-2a-
CRIg. The sequences and positions of primers used
for amplification are shown. The incorporated re-
striction sites are underlined, and the stop codon
is in boldface. CH, constant region of heavy chain;
TM, transmembrane domain; VH, variable region of
heavy chain. (B) CD59-2a-CRIg was expressed in CHO
cells, purified by anti-CD59a affinity chromatogra-
phy, subjected to 7.5% nonreducing SDS/PAGE, and
stained with Coomassie blue. Two major bands were
observed, corresponding to monomeric and dimeric
forms of CD59-2a-CRIg. (C) Purified protein was
loaded onto a Superdex 200 column. CD59-2a-CRIg
eluted as two peaks representing the dimer and
monomer. (D) Eluted protein from the dimer and
monomer peaks (indicated by the arrow) were ana-
lyzed by SDS/PAGE. Protein was visualized by silver
staining. (E) Identity of the peaks was confirmed by
Western blot analysis. Peak fractions were subjected
to SDS/PAGE under nonreducing and reducing
conditions, transferred to nitrocellulose, and then
probed with rat anti-mouse CRIg mAb (MBI4, gen-
erated in house). (F) CD59-2a-CRIg complement in-
hibitory function was assessed in an alternative
pathway hemolytic assay. The protective effect was
abolished when CD59a moiety was blocked with
anti-CD59 antibodies. Percent lysis was plotted against
protein concentration.
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CD59-2a-CRIg Reduces Posttraumatic Neurologic Disability and
Weight Loss. To test whether MAC inhibition by CD59-2a-CRIg
is protective in TBI, neurological performance and weight loss
were monitored up to 72 h postinjury in mice treated with CD59-
2a-CRIg or PBS as the control; sham-operated controls were
also included (Fig. S2). Anti-C5 therapies that blocked both C5a
and MAC were previously shown to be effective when delivered up
to 15 min postinjury (14). To test whether this therapeutic win-
dow could be expanded, mice were treated with CD59-2a-CRIg
30 min post-TBI and with a second dose 24 h later. Treatment
resulted in 50% reduction of the neurological severity score
(NSS) at 4 h compared with PBS controls (P < 0.001, two-way
ANOVA); improvement was maintained throughout the time
course and nearly complete at 72 h postinjury, when controls
remained neurologically impaired (NSS, 2.8 ± 0.7). Sham-operated
controls showed no neurological impairment (Fig. 4A). Weight loss
was monitored as an additional clinical outcome. PBS-treated
mice lost 13.3 ± 3.6% of preinjury weight at 48 h postinjury,
whereas mice treated with CD59-2a-CRIg displayed significantly
reduced weight loss (6.4 ± 3.7%; P < 0.01, two-way ANOVA),
regaining pre-TBI weight by 72 h. Sham-operated controls did
not lose weight (Fig. 4B). Together, these findings show that
treatment with CD59-2a-CRIg administered from 30 min post-
TBI promotes recovery after TBI.
CD59-2a-CRIg Reduces Inflammation, Mitochondrial Stress, and Axonal
Injury Post-TBI. To determine whether CD59-2a-CRIg blocked
MAC deposition and reduced brain inflammation, sagittal sections
from treated and control mice were stained for C9, a marker of
MAC deposition (14, 19–22) (Fig. 5 A–C), and Iba-1, a marker of
microglia/macrophages (14) (Fig. 5 D–F). Brain sections in sham
controls were negative for MAC staining (Fig. 5A and Figs. S3A
and S4A), whereas PBS-treated TBI mice displayed abundant,
widespread MAC deposition in the cortex (Fig. 5B), hippocampus
(Fig. S3B), and periventricular areas (Fig. S4B). Treatment with
CD59-2a-CRIg reduced MAC immunoreactivity in all brain areas
examined (Fig. 5C and Figs. S3C and S4C). Iba-1 immunostaining
in sham controls showed few, small immunolabeled cells (Fig. 5D
and Figs. S3D and S4D). PBS-treated TBI brains showed abun-
dant, large Iba-1–positive cells resembling reactive microglia (Fig.
5E and Figs. S3E and S4E); Iba-1 immunoreactivity was low in
brains of TBI mice treated with CD59-2a-CRIg (Fig. 5F and
Figs. S3F and S4F), demonstrating reduced inflammation.
To determine whether the observed improvement in neuro-
logical performance post-TBI in mice treated with CD59-2a-
CRIg is due to reduced neuronal damage, immunohistochemistry
using mitochondrial heat shock protein 70 (mtHSP70; mitochon-
drial stress marker) (Fig. 5 G–J) and amyloid precursor protein
(APP; axonal injury marker) (Fig. 5 J–L) was performed in all
brains. Sham controls showed no signs of mitochondrial stress
(Fig. 5G and Figs. S3G and S4G) or axonal injury (Fig. 5J and
Figs. S3J and S4J). Staining for mtHSP70 and APP was strongest
in PBS-treated TBI mice, in neurons located in proximity to the
site of impact (Fig. 5 H and K), in the hippocampal CA1 region
(Fig. S3 H and K), and in the perivascular area (Fig. S4 H and K).
In contrast, mtHSP70 and APP immunoreactivities were low in
brains of CD59-2a-CRIg–treated TBI mice (Fig. 5 I and L and
Figs. S3 I and L and S4 I and L), demonstrating that treatment
reduced mitochondrial stress and axonal injury. Quantification of
MAC staining showed abundant immunoreactivity (9.83 ± 1.07%;
range, 2.15–17.50%) of all examined brain areas in PBS-treated
TBI mice; staining was significantly lower in CD59-2a-CRIg–
treated TBI mice (0.51 ± 0.12%; range, 0.23–2.70%; P < 0.001,
two-way ANOVA) (Fig. 5M). Iba-1 immunoreactivity covered
4.97 ± 0.18% (range, 2.92–6.35%) of the brain areas in PBS-
treated TBI mice but was significantly lower in all areas in CD59-2a-
CRIg–treated TBI mice (1.12 ± 0.03%; range, 0.78–1.31%; P <
0.01–0.001, two-way ANOVA) (Fig. 5N). Quantification of immu-
nostaining for mtHSP70 and APP showed that CD59-2a-CRIg
treatment significantly reduced mitochondrial stress and axonal
Fig. 2. Dimerization of CD59-2a-CRIg increased the
affinity for C3b. CD59-2a-CRIg monomer (A) and
dimer (B) were flowed over a C3b-coated chip at
concentrations between 30 nM and 7.0 μM (mono-
mer) in duplicate and 8 nM–1.98 μM (dimer) in
triplicate (KD is mean ± SD). The equilibrium binding
response was measured. Apparent affinity (KD) was
determined by steady-state analysis (Insets show
one example).
Fig. 3. CD59-2a-CRIg homed to opsonized tissue
and inhibited MAC deposition in vivo. Mice were
treated immediately after TBI with either CD59-2a-
CRIg (20 mg/kg, i.v., n = 2) (A–C) or PBS (n = 3) as the
control (D–F). Brains were collected at 3 d postinjury
and consecutive sections immunostained for CRIg
to localize the CD59-2a-CRIg in situ (A and D), for
C3/C3dg to detect opsonized tissue (B and E), and
for C9 to detect MAC deposition (C and F). CD59-2a-
CRIg localized to areas of tissue injury at the impact
sites (asterisk in A) and was absent in PBS-treated mice
(D). C3 activation products (C3b/iC3b/C3dg) present at
impact sites (asterisks in B and E) colocalized with
CD59-2a-CRIg in treated mice (B). MAC deposition was
absent in the CD59-2a-CRIg–treated group (C) but
abundant at the impact site in controls (asterisk in
F). In all images, the impact site is enclosed in the
dotted line. (Scale bar, 500 μm.)
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injury in the cortex (mtHSP70, 3.25 ± 0.08% vs. 0.34 ± 0.03%,
P < 0.001; APP, 3.76 ± 0.06% vs. 1.74 ± 0.07%, P < 0.001, two-
way ANOVA), hippocampus (mtHSP70, 2.55 ± 0.20% vs. 0.05 ±
0.01%, P < 0.001; APP, 2.02 ± 0.11% vs. 0.44 ± 0.08%, P <
0.001, two-way ANOVA), and periventricular area (mtHSP70,
1.37 ± 0.12% vs. 0.12 ± 0.02%, P < 0.001; APP, 2.92 ± 0.12% vs.
0.41 ± 0.07%, P < 0.001, two-way ANOVA) (Fig. 5 O and P).
These findings show that CD59-2a-CRIg, administered 30 min
post-TBI and 24 h later, homes to sites of tissue injury, blocks
MAC deposition, and reduces inflammation, neuronal stress,
and further injury at 72 h post-TBI.
CD59-2a-CRIg Inhibits Inflammasome Activation Post-TBI. Precisely
how MAC induces nerve damage after TBI is unknown. Recent
reports showed that sublethal MAC triggers NLRP3 (nucleotide-
binding domain, leucine-rich repeat containing family, pyrin
domain-containing 3) inflammasome activation and release of
IL-1β (24, 25). We therefore tested whether MAC regulates
secondary inflammatory processes after TBI by inducing inflamma-
some activation in brain cells, leading to production of IL-1β, which
is known to be toxic to neurons (26, 27). In situ hybridization
demonstrated expression of IL-1β mRNA in injured brains of con-
trols at 72 h post-TBI. The IL-1β signal localized on Iba-1–positive
Fig. 4. CD59-2a-CRIg reduced neurologic disability
and weight loss after TBI. Shown are the NSS (A) and
weight loss (B) of mice treated with either CD59-2a-
CRIg (20 mg/kg) (n = 6) or PBS (n = 5) 30 min after TBI
and 24 h later. Asterisks indicate statistically signifi-
cant differences, with **P < 0.01 or ***P < 0.001
determined by two-way ANOVAwith Bonferroni post
hoc test.
Fig. 5. CD59-2a-CRIg reduced MAC deposition, in-
flammation, and neuronal damage in the cortex
at 3 d post-TBI. (A–L) Representative images of
immunostaining for C9/MAC (A–C), Iba-1 marker
of microglia/macrophages (D–F), mtHSP70 marker
of mitochondrial stress (G–I), and the APP marker of
acute axonal injury (J–L) in the cortex of uninjured
mice (A, D, G, and J; n = 3) or injured mice treated
with either PBS (B, E, H, and K; n = 5) or CD59-2a-
CRIg (C, F, I, and L; 20 mg/kg i.v.; n = 6) at 30 min
post-TBI and 24 h later, then killed at 72 h. Note in
the PBS-treated group intense C9/MAC staining in
close proximity to neurons (arrows in zoom B), Iba-1
immunoreactive cells closely apposed to neurons
(arrows in zoom E), and mtHSP70 and APP immu-
noreactivity in neuronal cell bodies (arrows in zoom
H and zoom K). [Scale bar, (A–L) 200 μm and (Insets)
50 μm.] (M–P) Quantification of C9/MAC (M), Iba-1
(N), mtHSP70 (O), and APP (P) immunoreactivity in
mouse brains showing that the intensity of staining
is significantly reduced for each marker in the cortex
(ctx), hippocampus (hc), and periventricular area
(pv) of CD59-2a-CRIg–treated mice compared with
PBS-treated controls. Statistically significant differ-
ences with **P < 0.01 or ***P < 0.001 are de-
termined by two-way ANOVA with Bonferroni post
hoc test.
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cells in brain areas located in close proximity to edema (Fig. 6
A, zoom A). These areas were also enriched in MAC-coated
cells (Fig. 6B), indicating that MAC triggers inflammasome
activation and IL-1β production in microglia. Treatment with
CD59-2a-CRIg post-TBI eliminated the IL-1β signal (Fig. 6C)
and MAC staining (Fig. 6D) in equivalent brain areas containing
Iba-1–positive cells. These findings show that CD59-2a-CRIg ad-
ministered after TBI inhibits MAC-induced inflammasome ac-
tivation and IL-1β production in microglia in the TBI brain.
Discussion
Clinical and experimental studies have implicated complement in the
neuroinflammatory and neurodegenerative sequelae to primary me-
chanical injury after TBI (3, 6, 7, 9, 11, 28). Therapeutic strategies
involving systemic complement inhibition have proven successful in
experimental TBI (6, 9–11) but have limited clinical relevance be-
cause of infection risk. Here we describe an anticomplement thera-
peutic, CD59-2a-CRIg, that homed to sites of brain injury in TBI,
blocked MAC formation, and delivered neuroprotection. This strat-
egy improves bioavailability; minimizes adverse effects due to sys-
temic inhibition; specifically targets the MAC, thereby maintaining
upstream activities; and provides membrane localization, which is
necessary for optimal CD59a function (29).
Complement is a major component of innate immunity and the
first-line defense against pathogens (13). Anticomplement therapies
should, ideally, target detrimental effects of complement while
maintaining anti-infection function, especially critical for TBI pa-
tients who suffer hospital-acquired sepsis far more frequently than
other patients (30), with an associated mortality rate as high as 37%
(31). Notably, selective inhibition of MAC in rodent models of brain
injury reduced pathology and clinical disability (20, 22). In TBI, the
pathological role of the MAC had not been tested due to lack of
specific MAC inhibitors; however, the recent description of a C6
antisense enabled testing (14). When administered before TBI, C6
antisense significantly reduced inflammation and neuroaxonal loss
and improved the neurologic outcome. C6 antisense therapy re-
quires several days pretreatment to reduce C6 levels, so it is not a
treatment option for TBI patients where a drug must be effective
quickly when administered postinjury; an ideal drug will also spare
upstream complement functions and home to the site of injury,
thereby minimizing systemic effects.
Homing agents that use a fragment of complement receptor
2 (CR2) for delivery to complement-opsonized tissue sites have
been described (32, 33). CR2 binds iC3b and, preferentially,
C3dg; fusion proteins comprising the C3dg-binding fragment of
CR2 linked to a complement regulator delivered therapy with
reduced infection risk when administered systemically in models
(33). We generated CD59a-based targeted therapeutics using
CRIg as the targeting domain and the IgG2a hinge to promote
dimerization (15). Preliminary analysis demonstrated that CD59a
positioned N-terminally relative to CRIg had better MAC inhibitory
function compared with constructs with C-terminal CD59a (Fig.
S1B). CRIg binds iC3b at a site within the C3c fragment; we pro-
pose that this alternative targeting domain will preferentially
distribute the homing agent to tissues where iC3b predominates
over C3dg. Thus, a CRIg-targeted agent may home to sites of
ongoing, or recent, complement activation and not to sites of
previous complement activation where C3dg may persist (34).
An additional advantage, conferred by the IgG2a hinge, is avidity;
dimerization will improve bioavailability and homing efficacy. This
effect was confirmed by SPR-dimeric CD59-2a-CRIg bound target
(KD = 0.55 μM) with an eightfold higher affinity than monomeric
CD59-2a-CRIg. Kinetic analysis of binding of another CRIg-tar-
geted reagent, CRIg-FH, to C3b was previously published (17);
however, a direct comparison with CD59-2a-CRIg cannot be
made because both CRIg and FH moieties of CRIg-FH bind C3b
and contribute to the interaction.
We previously described a mouse closed skull TBI model; a
2-cm weight drop caused severe and widespread inflammation and
neuropathology not only at the impact site but also in deeper areas
including the hippocampus and paraventricular area (14). Post-TBI
treatment with CD59-2a-CRIg inhibited inflammation and neuro-
axonal damage throughout the brain, showing that this targeted
anti-MAC therapeutic inhibited the secondary wave of pathology
that follows primary mechanical injury. Critically, we show that
CD59-2a-CRIg colocalized with its ligands (C3b/iC3b) in the in-
jured brain, reduced neuropathology, and improved neurologic
performance when administered 30 min after TBI. Whether ad-
ministration of CD59-2a-CRIg may be effective when administered
even later postinjury is an important question requiring further
exploration. The data suggest a therapeutic window of opportunity
for effective intervention after TBI to prevent secondary neuro-
logical damage, raising the prospect that such strategies may work
when administered immediately postinjury in humans, perhaps by
first responders at the scene or in the ambulance, as currently
happens with thrombolytics with a reported 4.5-h window (35).
The mechanisms of complement activation and MAC-induced
neurodegeneration after TBI are uncertain. Early reports showing
improved outcomes after TBI in mice treated with C1 inhibitor
implicate the classical and/or lectin pathway (36), whereas others
implicate the alternative pathway (6, 11). Cell damage caused by
mechanical shearing in TBI may expose axonal epitopes, cell con-
tents, and/or flipped membranes, all “danger” signals recognized by
C1q, resulting in antibody-independent classical pathway activation
and MAC formation (37). MAC then breaches target membranes,
releasing cell contents and driving further complement activation
and opsonization of targets by C3b/iC3b, providing ligands for CR3-
mediated phagocytic clearance of damaged tissue (38, 39). We
observed MAC deposition on microglia in TBI, especially in
Fig. 6. CD59-2a-CRIg reduced IL-1β production by microglia/macrophages at
3 d post-TBI. Shown are representative images of immunostaining for the
Iba-1 marker of microglia/macrophages, in situ hybridization for IL-1βmRNA,
and immunostaining for C9/MAC in the brains of injured mice treated with
either PBS (A and B; n = 5) or CD59-2a-CRIg (C and D; 20 mg/kg i.v.; n = 6) at
30 min post-TBI and 24 h later. In PBS-treated mice, the Iba-1–positive
microglia/macrophages (A, blue) colocalized with the IL-1β mRNA signal
(A, red) especially in areas of edema, indicated by the extravasation of eryth-
rocytes (asterisk in zoom A). Cells coated with MAC (arrows in B, red) were also
found in consecutive sections, in close proximity to edema (asterisk in B). In the
CD59-2a-CRIg–treated mice, Iba-1–positive microglia/macrophages (C, blue) were
negative for IL-1β mRNA in equivalent brain areas in close proximity to edema
(asterisk in zoom C). No MAC signal (D) was detected in consecutive sections, in
close proximity to edema (asterisk in D). In B and D, nuclei are stained with
hematoxylin (in blue). (Scale bar in A–D and zoom, 25 μm.)
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proximity to a leaky blood brain barrier. Recent studies have
shown that MAC can elicit secretion of proinflamamatory cy-
tokines such as IL-1β and IL-18 in vitro and in vivo via NLRP3
inflammasome activation (24, 25). Here we show that MAC-
positive microglia express mRNA for IL1-β, implicating sublytic
MAC in driving cells toward a proinflammatory state that may
contribute to tissue damage, endothelial permeability, and ex-
pression of adhesion molecules (40), facilitating recruitment of
inflammatory cells into the brain.
In summary, we show that CD59-2a-CRIg homes to opsonized
surfaces and protects fromMAC-mediated damage in vitro and in vivo
in the TBI model, the latter with a therapeutic window that permits
treatment postinjury. A homingMAC inhibitor is attractive for therapy
because it minimizes systemic effects and risk of infection. Our findings
provide a rational basis for a novel future therapeutic strategy for TBI.
Materials and Methods
Preparation of CD59-2a-CRIg. DNA encoding the signal peptide and the ex-
tracellular domain ofmouse CD59a (C-terminal residue Lys72) was cloned into
expression vector pDR2ΔEF1α (a gift from I. Anegon, INSERM U437, Nantes,
France) (41). DNA encoding the extracellular domain ofmouse CRIg (residues 1–162)
was cloned downstream of CD59. To generate CD59-2a-CRIg, DNA encoding the
hinge region of mouse IgG2a was cloned between CD59Aand CRIg. CD59-2a-CRIg
was isolated from the supernatant of stably transfected CHO cell clones cultured in
CELLine AD1000 (Integra Biosciences) using anti-CD59 (clone 7A6) affinity column.
Purified protein was analyzed by 7.5% SDS/PAGE.
Closed Head Injury Model. Focal TBI was induced as described using a stan-
dardized free-falling weight drop device (42).
Animals. All experiments were approved by the Academic Medical Center
Animal Ethics Committee (DNL 102705) and complied with Dutch national
guidelines for the care of experimental animals.
Statistical Analysis. All statistical analyses were performed using GraphPad
Prism 7.0 analysis software. Two-way ANOVA, including Bonferroni correction
and post hoc tests, was used for all tests with statistically significant differences
when P < 0.05. All values are given as means ± SEM unless otherwise indicated.
ACKNOWLEDGMENTS. We thank Iliana Michailidou for technical support
with in situ hybridization. This work was funded by a Cardiff University PhD
studentship (to M.M.R.) and Brain Foundation of the Netherlands Fellowship
F2010 (1)-05 (to V.R.).
1. Max JE, Robertson BA, Lansing AE (2001) The phenomenology of personality change due to
traumatic brain injury in children and adolescents. J Neuropsychiatry Clin Neurosci 13(2):161–170.
2. Salmond CH, Sahakian BJ (2005) Cognitive outcome in traumatic brain injury survi-
vors. Curr Opin Crit Care 11(2):111–116.
3. Bellander BM, Singhrao SK, Ohlsson M, Mattsson P, Svensson M (2001) Complement acti-
vation in the human brain after traumatic head injury. J Neurotrauma 18(12):1295–1311.
4. Burk AM, et al. (2012) Early complementopathy after multiple injuries in humans.
Shock 37(4):348–354.
5. Stahel PF, et al. (2001) Intrathecal levels of complement-derived soluble membrane
attack complex (sC5b-9) correlate with blood-brain barrier dysfunction in patients
with traumatic brain injury. J Neurotrauma 18(8):773–781.
6. Leinhase I, et al. (2006) Reduced neuronal cell death after experimental brain injury in
mice lacking a functional alternative pathway of complement activation. BMC
Neurosci 7:55.
7. Stahel PF, et al. (2009) Absence of the complement regulatory molecule CD59a leads to
exacerbated neuropathology after traumatic brain injury inmice. J Neuroinflammation 6:2.
8. Kaczorowski SL, Schiding JK, Toth CA, Kochanek PM (1995) Effect of soluble com-
plement receptor-1 on neutrophil accumulation after traumatic brain injury in rats.
J Cereb Blood Flow Metab 15(5):860–864.
9. Leinhase I, et al. (2006) Pharmacological complement inhibition at the C3 convertase
level promotes neuronal survival, neuroprotective intracerebral gene expression, and
neurological outcome after traumatic brain injury. Exp Neurol 199(2):454–464.
10. Sewell DL, et al. (2004) Complement C3 and C5 play critical roles in traumatic brain
cryoinjury: Blocking effects on neutrophil extravasation by C5a receptor antagonist.
J Neuroimmunol 155(1-2):55–63.
11. Leinhase I, et al. (2007) Inhibition of the alternative complement activation pathway
in traumatic brain injury by a monoclonal anti-factor B antibody: A randomized
placebo-controlled study in mice. J Neuroinflammation 4:13.
12. Holers VM (2008) The spectrum of complement alternative pathway-mediated dis-
eases. Immunol Rev 223:300–316.
13. Ricklin D, Hajishengallis G, Yang K, Lambris JD (2010) Complement: A key system for
immune surveillance and homeostasis. Nat Immunol 11(9):785–797.
14. Fluiter K, Opperhuizen AL, Morgan BP, Baas F, Ramaglia V (2014) Inhibition of the
membrane attack complex of the complement system reduces secondary neuro-
axonal loss and promotes neurologic recovery after traumatic brain injury in mice.
J Immunol 192(5):2339–2348.
15. Ruseva MM, Morgan BP, Harris CL (2009) Targeting sites of complement activation by
engineering selective drug delivery. Mol Immunology 46:2865.
16. Meri S, et al. (1990) Human protectin (CD59), an 18,000-20,000 MW complement lysis re-
stricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71(1):
1–9.
17. Qiao Q, et al. (2014) A novel CRIg-targeted complement inhibitor protects cells from
complement damage. FASEB J 28(11):4986–4999.
18. Helmy KY, et al. (2006) CRIg: A macrophage complement receptor required for
phagocytosis of circulating pathogens. Cell 124(5):915–927.
19. Pratt JR, Basheer SA, Sacks SH (2002) Local synthesis of complement component C3
regulates acute renal transplant rejection. Nat Med 8(6):582–587.
20. Mead RJ, Singhrao SK, Neal JW, Lassmann H, Morgan BP (2002) The membrane attack
complex of complement causes severe demyelination associated with acute axonal
injury. J Immunol 168(1):458–465.
21. Piddlesden SJ, et al. (1994) Soluble recombinant complement receptor 1 inhibits in-
flammation and demyelination in antibody-mediated demyelinating experimental
allergic encephalomyelitis. J Immunol 152(11):5477–5484.
22. Ramaglia V, et al. (2007) The membrane attack complex of the complement system is
essential for rapid Wallerian degeneration. J Neurosci 27(29):7663–7672.
23. Ma Y, et al. (2015) Protein kinase cα regulates the expression of complement receptor
Ig in human monocyte-derived macrophages. J Immunol 194(6):2855–2861.
24. Laudisi F, et al. (2013) Cutting edge: The NLRP3 inflammasome links complement-
mediated inflammation and IL-1β release. J Immunol 191(3):1006–1010.
25. Triantafilou K, Hughes TR, Triantafilou M, Morgan BP (2013) The complement
membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 in-
flammasome activation. J Cell Sci 126(Pt 13):2903–2913.
26. Rossi S, et al. (2014) Interleukin-1β causes excitotoxic neurodegeneration andmultiple sclerosis
disease progression by activating the apoptotic protein p53. Mol Neurodegener 9:56.
27. Lai AY, Swayze RD, El-Husseini A, Song C (2006) Interleukin-1 beta modulates AMPA
receptor expression and phosphorylation in hippocampal neurons. J Neuroimmunol
175(1-2):97–106.
28. Rostami E, et al. (2013) The terminal pathway of the complement system is activated
in focal penetrating but not in mild diffuse traumatic brain injury. J Neurotrauma
30(23):1954–1965.
29. Zhang HF, Yu J, Bajwa E, Morrison SL, Tomlinson S (1999) Targeting of functional
antibody-CD59 fusion proteins to a cell surface. J Clin Invest 103(1):55–61.
30. Mascia L, et al.; Sepsis Occurrence in Acutely Ill Patients (SOAP) Investigators (2008)
Extracranial complications in patients with acute brain injury: A post-hoc analysis of
the SOAP study. Intensive Care Med 34(4):720–727.
31. Plurad DS, et al. (2010) The association of race and survival from sepsis after injury.
Am Surg 76(1):43–47.
32. Song H, et al. (2003) Complement receptor 2-mediated targeting of complement
inhibitors to sites of complement activation. J Clin Invest 111(12):1875–1885.
33. Atkinson C, et al. (2005) Targeted complement inhibition by C3d recognition ame-
liorates tissue injury without apparent increase in susceptibility to infection. J Clin
Invest 115(9):2444–2453.
34. Zhang R, Zheng ZY, Lin JS, Qu LJ, Zheng F (2012) The continual presence of C3d but
not IgG glomerular capillary deposition in stage I idiopathic membranous nephrop-
athy in patients receiving corticosteroid treatment. Diagn Pathol 7:109.
35. Dorado L, Millán M, Dávalos A (2014) Reperfusion therapies for acute ischemic stroke:
An update. Curr Cardiol Rev 10(4):327–335.
36. Longhi L, et al. (2009) C1-inhibitor attenuates neurobehavioral deficits and reduces
contusion volume after controlled cortical impact brain injury in mice. Crit Care Med
37(2):659–665.
37. Baas F, Ramaglia V (2014) Uncovering the path to neurodegeneration from playingfield to
battlefield. Traumatic Brain Injury, eds Sadaka F, Quinn T (Intech, Rijeka, Croatia), pp 79–106.
38. Reichert F, Rotshenker S (2003) Complement-receptor-3 and scavenger-receptor-AI/II
mediated myelin phagocytosis in microglia and macrophages.Neurobiol Dis 12(1):65–72.
39. Rotshenker S (2003) Microglia and macrophage activation and the regulation of
complement-receptor-3 (CR3/MAC-1)-mediated myelin phagocytosis in injury and
disease. J Mol Neurosci 21(1):65–72.
40. Rothwell NJ, Luheshi GN (2000) Interleukin 1 in the brain: Biology, pathology and
therapeutic target. Trends Neurosci 23(12):618–625.
41. Charreau B, et al. (1994) Protection of rat endothelial cells from primate complement-
mediated lysis by expression of human CD59 and/or decay-accelerating factor.
Transplantation 58(11):1222–1229.
42. Flierl MA, et al. (2009) Mouse closed head injury model induced by a weight-drop
device. Nat Protoc 4(9):1328–1337.
43. Morgan BP (2000) Measurement of complement hemolytic activity, generation of
complement-depleted sera, and production of hemolytic intermediates.Methods Mol
Biol 150:61–71.
44. Harris CL, et al. (2003) Characterization of the mouse analogues of CD59 using novel
monoclonal antibodies: Tissue distribution and functional comparison. Immunology
109(1):117–126.
45. Ruseva MM, Heurich M (2014) Purification and characterization of human and mouse
complement C3. Methods Mol Biol 1100:75–91.
14324 | www.pnas.org/cgi/doi/10.1073/pnas.1513698112 Ruseva et al.
